MA46890A - Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme - Google Patents
Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long termeInfo
- Publication number
- MA46890A MA46890A MA046890A MA46890A MA46890A MA 46890 A MA46890 A MA 46890A MA 046890 A MA046890 A MA 046890A MA 46890 A MA46890 A MA 46890A MA 46890 A MA46890 A MA 46890A
- Authority
- MA
- Morocco
- Prior art keywords
- complications
- acute
- improvement
- reduction
- long
- Prior art date
Links
- FYZPCMFQCNBYCY-WIWKJPBBSA-N Insulin degludec Chemical compound CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC(O)=O)C(O)=O)C(O)=O)NC1=O)[C@@H](C)O)[C@@H](C)CC FYZPCMFQCNBYCY-WIWKJPBBSA-N 0.000 title 1
- 230000001154 acute effect Effects 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 230000002641 glycemic effect Effects 0.000 title 1
- 108010050259 insulin degludec Proteins 0.000 title 1
- 229960004225 insulin degludec Drugs 0.000 title 1
- 230000007774 longterm Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16200993 | 2016-11-28 | ||
| EP17162803 | 2017-03-24 | ||
| EP17174687 | 2017-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46890A true MA46890A (fr) | 2021-04-28 |
Family
ID=60702634
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA046890A MA46890A (fr) | 2016-11-28 | 2017-11-28 | Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11673933B2 (enExample) |
| EP (1) | EP3544682A1 (enExample) |
| JP (1) | JP2019535791A (enExample) |
| CN (1) | CN110099719A (enExample) |
| MA (1) | MA46890A (enExample) |
| WO (1) | WO2018096163A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3544682A1 (en) | 2016-11-28 | 2019-10-02 | Novo Nordisk A/S | Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications |
| JP7193455B2 (ja) | 2016-11-28 | 2022-12-20 | ノヴォ ノルディスク アー／エス | 心血管状態におけるインスリンデグルデク |
| TWI797133B (zh) | 2017-06-09 | 2023-04-01 | 丹麥商諾佛 儂迪克股份有限公司 | 用於經口投予的固體組成物 |
| US20230158234A1 (en) * | 2021-11-22 | 2023-05-25 | Colleen Cook | Method of Insulin Administration |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2283025T3 (es) | 1996-08-30 | 2007-10-16 | Novo Nordisk A/S | Derivados de glp-1.1. |
| GB0309154D0 (en) | 2003-01-14 | 2003-05-28 | Aventis Pharma Inc | Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia |
| WO2005012347A2 (en) | 2003-08-05 | 2005-02-10 | Novo Nordisk A/S | Novel insulin derivatives |
| AU2013241776B2 (en) * | 2012-03-28 | 2017-11-02 | Sanofi-Aventis Deutschland Gmbh | Basal insulin therapy |
| EP2976096B1 (en) * | 2013-03-20 | 2019-02-27 | Novo Nordisk A/S | Insulin dosing regimen |
| US10137172B2 (en) * | 2013-04-30 | 2018-11-27 | Novo Nordisk A/S | Administration regime |
| EP3544682A1 (en) | 2016-11-28 | 2019-10-02 | Novo Nordisk A/S | Insulin degludec for improvement of glycaemic control and reduction of acute and long-term diabetes complications |
-
2017
- 2017-11-28 EP EP17816532.0A patent/EP3544682A1/en not_active Withdrawn
- 2017-11-28 JP JP2019528540A patent/JP2019535791A/ja not_active Withdrawn
- 2017-11-28 CN CN201780073532.XA patent/CN110099719A/zh not_active Withdrawn
- 2017-11-28 US US16/463,594 patent/US11673933B2/en active Active
- 2017-11-28 WO PCT/EP2017/080603 patent/WO2018096163A1/en not_active Ceased
- 2017-11-28 MA MA046890A patent/MA46890A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN110099719A (zh) | 2019-08-06 |
| JP2019535791A (ja) | 2019-12-12 |
| US20200181222A1 (en) | 2020-06-11 |
| US11673933B2 (en) | 2023-06-13 |
| WO2018096163A1 (en) | 2018-05-31 |
| EP3544682A1 (en) | 2019-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46890A (fr) | Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme | |
| EP3746870A4 (en) | ECLIPSE CURSOR FOR VIRTUAL CONTENT IN MIXED REALITY DISPLAYS | |
| EP3681563A4 (en) | USER EXPERIENCE FOR INFUSION PUMPS | |
| SG11202002804SA (en) | Recombinant collagen and elastin molecules and uses thereof | |
| EP3437495A4 (en) | CARTRIDGE FOR TASTE INHALER AND TASTE INHALATOR | |
| EP3323873A4 (en) | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | |
| EP3392325A4 (en) | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | |
| MX380322B (es) | Compuestos co-agonistas del glucagon y peptido-1 similar al glugacon (glp-1). | |
| EP3327101A4 (en) | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | |
| IL240285A0 (en) | Biomarkers for type ii diabetes and their uses | |
| EP3450523A4 (en) | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | |
| EP3018186A4 (en) | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | |
| BR112018067731A2 (pt) | coagonistas de glucagon e glp-1 para o tratamento de obesidade | |
| PE20170768A1 (es) | Anticuerpos de union a protofibrillas ab mejorados | |
| EP3302621A4 (en) | PROCESS-BASED PROGRAMMING FOR INFUSION PUMPS | |
| EP3425025A4 (en) | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | |
| GB2553706B (en) | Electro-optic and thermo-optic modulator | |
| MA49678A (fr) | Compositions sous forme d'une solution aqueuse injectable comprenant au moins l'insuline humaine a21g et un suppresseur de glucagon a action prandiale | |
| EP3541429A4 (en) | INTRATHECAL ADMINISTRATION OF RECOMBINANT ADENO-ASSOCIATED VIRUS CODING FOR METHYL-CPG-BINDING PROTEIN 2 | |
| EP2884334A4 (en) | LIQUID CRYSTAL DISPLAY ELEMENT | |
| EP3570816A4 (en) | STABLE LIQUID COMPOSITION COMPRISING BOTULIN TOXIN | |
| SI3452312T1 (sl) | Ocenjevanje elektromehanskih veličin s pomočjo digitalnih slik in tehnik filtriranja na osnovi modela | |
| EP3530716A4 (en) | LIQUID CRYSTAL COMPOSITION FOR LIGHT CONTROL AND LIQUID CRYSTAL LIGHT CONTROL | |
| EP3334755A4 (en) | Improved cell-permeable reprogramming factor (icp-rf) recombinant protein and use thereof | |
| PT3630967T (pt) | Protease e polipéptido de ligação para o-glicoproteínas |